Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Update

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 7,780,000 shares, a growth of 94.5% from the December 15th total of 4,000,000 shares. Approximately 4.2% of the shares of the stock are short sold. Based on an average trading volume of 100,730,000 shares, the days-to-cover ratio is presently 0.1 days.

Tonix Pharmaceuticals Price Performance

Shares of NASDAQ:TNXP traded up $0.01 during trading on Wednesday, reaching $0.23. The stock had a trading volume of 65,830,587 shares, compared to its average volume of 67,687,922. The stock has a market capitalization of $43.42 million, a PE ratio of 0.00 and a beta of 2.02. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. Tonix Pharmaceuticals has a 52 week low of $0.12 and a 52 week high of $12.48. The business’s 50-day moving average price is $0.25 and its 200 day moving average price is $0.31.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The company had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. As a group, equities analysts predict that Tonix Pharmaceuticals will post -17.63 earnings per share for the current year.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on Tonix Pharmaceuticals in a report on Thursday, January 9th. They set a “hold” rating for the company.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.